UCB
Pharmaceutical companyAI in United StatesAI. FDA records under 3 spellings of its name, each linked to the record. See the UCB group view.
- Records across the group: 58, 3 entitiesAI
- Drug applications: 51
- OPDP letters: 4
- Drug recalls: 3
Records by Year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date, UCB and its 2 subsidiaries
Latest Records
Newest first across sources; each opens the record| Date | Record | Source |
|---|---|---|
| May 8, 2026 | cimzia (certolizumab pegol), 2x200mg/mL PREFILLED SYRINGES (2 single-dose), Rx ONLY, Manufactured by: UCB Inc., Smyrna, GA 30080, a) NDC 504Class II · Lack of Assurance of Sterility | Drug recalls |
| Sep 9, 2025 | Untitled letter: RYSTIGGOOffice of Prescription Drug Promotion | OPDP letters |
| Sep 9, 2025 | Untitled letter: BIMZELXOffice of Prescription Drug Promotion | OPDP letters |
| Sep 9, 2025 | Untitled letter: BIMZELXOffice of Prescription Drug Promotion | OPDP letters |
| Sep 9, 2025 | Untitled letter: BIMZELXOffice of Prescription Drug Promotion | OPDP letters |
Subsidiaries and Divisions
2 firms in the UCB group, most records first- Schwarz Pharma4 records
- UCB Biosciences1 records
Names and Identifiers
- Appears as
- Website
- ucb.com
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built